We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioPlus Acquisition Corporation | NASDAQ:BIOSU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.80 | 10.31 | 11.85 | 0 | 01:00:00 |
BioPlus Acquisition Corp.
260 Madison Avenue
Suite 800
New York, New York 10026
October 4, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: | BioPlus Acquisition Corp. |
Registration Statement on Form S-4
Filed May 15, 2023
File No. 333-271915
Ladies and Gentleman:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the Securities Act), BioPlus Acquisition Corp. (we, us, our, or the Company) hereby submits this letter to notify the Securities and Exchange Commission (the Commission) of our withdrawal of our Registration Statement on Form S-4 (File No. 333-271915) initially filed with the Commission on May 15, 2023, together with all exhibits and amendments thereto (the Registration Statement), because the Company has elected not to proceed with the business combination contemplated by the Registration Statement at this time. The Registration Statement was not declared effective and no securities have been issued or sold under the Registration Statement.
The Company acknowledges that no refund will be made for fees paid to the Commission in connection with the filing of the Registration Statement. However, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use should the Company proceed with the filing of a subsequent registration statement meeting the requirements of Rule 457(p) promulgated under the Securities Act.
Thank you for your assistance with this matter. If you have any questions or comments concerning this request, please contact our legal counsel, Peter Byrne of Cooley LLP, at pbyrne@cooley.com.
Sincerely, |
/s/ Ross Haghighat |
Ross Haghighat |
Chief Executive Officer, Chief Financial Officer and Director |
cc: | Peter Byrne, Cooley LLP |
1 Year BioPlus Acquisition Chart |
1 Month BioPlus Acquisition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions